Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balugrastim dose-finding study in pediatric solid tumors receiving chemotherapy
2012-005432-28Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of balugrastim in chemotherapy-induced neutropenia (CIN) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Area under the curve of absolute neutrophil count. Started Aug 2013; status: terminated.
02
Drugs
balugrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on 2012-005432-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005432-28.